News
RADIANT Trials: Everolimus Outshines Placebo in Neuroendocrine Tumors
- Author:
- Sara Freeman
Major Finding: Everolimus plus octreotide LAR was associated with a median progression-free survival of 16.4 months vs. 11.3 months for octreotide...
News
In the Pipeline: Positive Early Results with Pazopanib in Bladder Cancer
- Author:
- Sara Freeman
Major Finding: Four patients (22%) experienced a partial response, and 11 (61%) had stable disease.Data Source: Ongoing phase II, single-center,...
News
In the Pipeline: Tivozanib Tops Placebo in Renal Cell Carcinoma
- Author:
- Sara Freeman
Major Finding: Compared with placebo, tivozanib more than doubled the percentage of patients who were progression free at the end of the 12-week,...
News
In the Pipeline: Tivozanib Tops Placebo in Renal Cell Carcinoma
- Author:
- Sara Freeman
Major Finding: Compared with placebo, tivozanib more than doubled the percentage of patients who were progression free at the end of the 12-week,...
News
In the Pipeline: Figitumumab Active in Refractory Ewing's Sarcoma
- Author:
- Sara Freeman
Major Finding: Median progression-free survival was 1.87 months and median overall survival was 8.87 months, with greater effect in those with a...
News
Quality of Life Varies for Prostate Ca Treatments
- Author:
- Sara Freeman
News
Bevacizumab Confirmed Beneficial For First-Line Ovarian Cancer Treatment
- Author:
- Sara Freeman
Major Finding: Median progression-free survival was 19.0 vs. 17.3 months (hazard ratio, 0.81; P = .0041) in patients treated with bevacizumab in...
News
Balloon Kyphoplasty Relieves Compression Fracture Pain in Cancer Patients
- Author:
- Sara Freeman
Major Finding: One month post procedure, surgically treated patients experienced a significant 8.5-point decrease in Roland-Morris Disability...
News
Cetuximab Adds No Benefit to First-Line Regimen for Metastatic Colorectal Cancer
- Author:
- Sara Freeman
Major Finding: Progression-free survival did not significantly differ between the standard FLOX, FLOX-cetuximab, and “stop/go” FLOX-cetuximab arms...
News
Cetuximab Adds No Benefit to First-Line Regimen for Metastatic Colorectal Cancer
- Author:
- Sara Freeman
Major Finding: Progression-free survival did not significantly differ between the standard FLOX, FLOX-cetuximab, and “stop/go” FLOX-cetuximab arms...
News
Long-Term Breast Radiotherapy Trials at Odds Over Risk of Second Malignancies
- Author:
- Sara Freeman
Major Finding: No increased risk of contralateral breast cancer or second malignancies was observed after 30 years’ follow-up in the Stockholm...
News
Regional Hyperthermia Plus Chemo Helps High-Risk, Nonextremity, Soft Tissue Sarcomas
- Author:
- Sara Freeman
Major Finding: At 2-years, progression-free survival was 70% and disease-free survival was 56% in patients with high-risk, nonextremity, soft...
News
Mitomycin C Offers Alternative, but Cisplatin-Based Chemoradiation Remains Standard in Head and Neck Cancer
- Author:
- Sara Freeman
Major Finding: At 3 years, more patients who received weekly chemoradiation with cisplatin than MMC were free of distant metastases (HR, 0.622; P...
News
Prostate Cancer Treatments' Quality of Life Effects Differ Long Term
- Author:
- Sara Freeman
Major Finding: Radical retropubic prostatectomy (RRP) was associated with significantly more urinary incontinence and sexual dysfunction than were...
News
Malnutrition Widespread in Cancer Patients; Counseling Prolongs Survival
- Author:
- Sara Freeman
Major Finding: One study found that all cancer patients were malnourished, more than 70% of them moderately or severely. But patients who were...